NCT06801743 WHEN DO WE HAVE to PERFORM CARDIAC MAGNETIC RESONANCE in PATIENTS REFERRED for PREMATURE VENTRICULAR COMPLEXES by THEIR CARDIOLOGISTS
| NCT ID | NCT06801743 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Premature Ventricular Complexes |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-11-27 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-11-27 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Premature ventricular complexes (PVC) are a common entity affecting approximatively 20% of the general population. It can be discovered incidentally on electrocardiogram (ECG) or associated with symptoms with a wide spectrum from palpitations, chest pain, to syncope. The initial and non invasive assessment includes holter ECG monitoring, a transthoracic echocardiography (TTE) and an exercise stress test to rule out structural heart disease (SHD), and referred to as benign or "idiopathic" ventricular arrhythmias (IVA). However, these exams may fail to identify subtle myocardial abnormalities such as arrhythmogenic right ventricle dysplasia (ARVD), apical hypertrophic cardiomyopathy, healed myocarditis, ischemic or non-ischemic cardiomyopathies. Cardiac magnetic resonance (CMR) imaging is the gold standard modality to assess regional and global ventricular function. It is also a unique modality to non-invasively detect myocardial edema, myocardial fatty replacement, focal and diffuse fibrosis and could potentially identify SHD in patients with PVC. However, the role of CMR is uncertain, recommended in case of atypical presentation or when the initial assessment can't exclude a cardiomyopathy (recommendations class IIa). This study sought to determine whether and when CMR can be performed to provide diagnosis or prognostic information complementary to initial assessment in patients referred for PVC by their cardiologists.
Eligibility Criteria
Inclusion Criteria: * patients with PVC who have performed ECG, Holter ECG and a CMR Exclusion Criteria: * patient showing opposition tu use his personal data for the reseach, * patient unable to express his opposition, * patient deprived of liberty, * patient with language issues (speaking or writing French)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06801743 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Premature Ventricular Complexes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06801743 currently recruiting?
Yes, NCT06801743 is actively recruiting participants. Contact the research team at vermes.emmanuelle@chu-amiens.fr for enrollment information.
Where is the NCT06801743 trial being conducted?
This trial is being conducted at Salouël, France.
Who is sponsoring the NCT06801743 clinical trial?
NCT06801743 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 200 participants.